EGFR and breast carcinoma: Both 111In- and 177Lu-labelled bsRICs were also effective for treatment of TrR1 human breast cancer xenografts that are HER2 and EGFR-positive, but have acquired resistance to trastuzumab, but these tumours were less sensitive than MDA-MB-231/H2N tumour xenografts (Razumienko et al. 2016).